Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of two doses of crizanlizumab in sickle cell disease
2017-001746-10Phase 3Unknown
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crizanlizumab in sickle cell disease (SCD) (3 arms), sponsored by Novartis. Primary endpoint: Annualized rate of VOC events leading to healthcare visit over first year. Status: unknown.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-001746-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001746-10.